Clinical Trials
Wednesday, December 18th, 2013
ASA: 11/14/13 Background and Purpose—Patients with acute ischemic stroke benefit from rapid evaluation and treatment, and timely brain imaging is a necessary component. We determined the effect of a targeted behavioral intervention on door-to-imaging time (DIT) among patients with ischemic stroke treated with tissue-type plasminogen activator. Second, we examined the variation in DIT accounted for by […]
Clinical Trials
Saturday, December 14th, 2013
NIH: Thursday, December 12, 2013 Stroke remains number one cause of disability and fourth leading cause of death in the United States A network of 25 regional stroke centers working with nearby satellite facilities will span the country, have teams of researchers representing every medical specialty needed for stroke care and will address the three […]
Clinical Trials
Saturday, December 14th, 2013
BMC Medical Research Methodology: December 7, 2013 Designs and analyses of clinical trials with a time-to-event outcome almost invariably rely on the hazard ratio to estimate the treatment effect and implicitly, therefore, on the proportional hazards assumption. However, the results of some recent trials indicate that there is no guarantee that the assumption will hold. Here, […]
Clinical Trials
Saturday, December 14th, 2013
BMJ: 12/5/13 FDA investigator Thomas Marciniak has spoken out over drug companies and missing or “bad” data, most famously over rosiglitazone. He tells Deborah Cohenhow he believes the current research and development process is broken The clinical trial system is broken and it’s getting worse, according to longstanding Food and Drug Administration investigator, Thomas Marciniak. For seasoned […]
Clinical Trials
Saturday, December 14th, 2013
Wiley: DEC 1, 2013 Background Our randomized controlled trial of a multifaceted evidence-based intervention for improving the inpatient management of fever, hyperglycemia, and swallowing dysfunction in the first three-days following stroke improved outcomes at 90 days by 15%. We designed a quantitative process evaluation to further explain and illuminate this finding. Methods Blinded retrospective medical record […]
Clinical Trials
Saturday, December 14th, 2013
Biostatistics: September 25, 2013 The accuracy of published medical research is critical for scientists, physicians and patients who rely on these results. However, the fundamental belief in the medical literature was called into serious question by a paper suggesting that most published medical research is false. Here we adapt estimation methods from the genomics community to […]
Clinical Trials
Saturday, December 14th, 2013
STROKEAHA: December 5, 2013 Background and Purpose—Early poststroke aphasia rehabilitation effects and their functional MRI (fMRI) correlates were investigated in a pilot, controlled longitudinal study. Methods—Twelve patients with mild/moderate aphasia (8 Broca, 3 anomic, and 1 Wernicke) were randomly assigned to daily language rehabilitation for 2 weeks (starting 2.2 [mean] days poststroke) or no rehabilitation. The […]
Clinical Trials
Saturday, December 14th, 2013
STROKEAHA: November 26, 2013 Background and Purpose—Rapid, accurate, and reliable identification of the computed tomography angiography spot sign is required to identify patients with intracerebral hemorrhage for trials of acute hemostatic therapy. We sought to assess the accuracy and interobserver agreement for spot sign identification. Methods—A total of 131 neurology, emergency medicine, and neuroradiology staff and […]
Clinical Trials
Saturday, December 14th, 2013
STROKEAHA: November 19, 2013 Early Short-Term Dual Antiplatelet Treatment for Stroke Prevention The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial tested the effect of early dual antiplatelet treatment for the prevention of secondary stroke within the first 90 days following a qualifying transient ischemic attack (TIA) or minor stroke in 5170 […]
Clinical Trials
Saturday, December 14th, 2013
STROKEAHA: November 12, 2013 Is it appropriate to enroll into a clinical trial (and hence randomize to either medical or endovascular therapy) a 45-year-old patient who presents within 3 hours of onset of disabling symptoms resulting from a left M1 occlusion? This is the question many of us have faced in the course of the past […]
